This site is intended for healthcare professionals
One Neuroscience and Pain Learning Zone
Declaration of sponsorship Novartis Pharma AG

Epilepsy

Declaration of sponsorship Novartis Pharma AG
Read time: 200 mins
Last updated:6th Jul 2021
Recognise the symptoms of epilepsy and consider some ways in which healthcare professionals can improve outcomes for patients and carers.

With onset commonly occurring in childhood and adolescence, epilepsy is a chronic, heterogenous condition in which patients experience recurrent and seemingly unprovoked seizures1,2. About 46 million people worldwide have active epilepsy3. Despite being common, classifying, diagnosing and treating epilepsy in adults and children can be difficult. Only about half of adults became seizure free with their first anti-epileptic drug (AED), for example4 and treatment resistance remains a major challenge. Paradoxically, some AEDs can even exacerbate seizures. Advances in AEDs reduce the risk of certain adverse events that proved problematical with some older drugs, such as neuropsychological side effects.

Meet the Experts

  • Professor Lieven Lagae from the University of Leuven, Belgium (KUL) is Head of the Paediatric Neurology Department of the KUL University Hospitals and Director of the Childhood Epilepsy Program at the KUL University Hospitals
  • Professor Yuwu Jiang is Director of the Department of Paediatrics and the Centre for Children with Epilepsy, Peking University First Hospital
  • Professor Patrick Kwan is Professor of Neurology at the Department of Neuroscience at Monash University and Head of Epilepsy at the Alfred Hospital in Melbourne, Australia
  • Dr Andrew Neal is a consultant neurologist and epileptologist based in Melbourne, Australia. He is also a research fellow at Monash University with a special interest in epilepsy surgery and intracranial-EEG
  • Professor Terence O’Brien is a neurologist specialising in the treatment of epilepsy. He is Head of the Department of Neuroscience at Monash Central Clinical School
  • Professor Piero Perucca is an Associate Professor from the Department of Neuroscience at the Monash Central Clinical School. He is also a consultant neurologist and epileptologist at the Royal Melbourne Hospital, and at Alfred Health

The incidence of paediatric epilepsy is up to 187 cases per 100,000 of the population5 and healthcare professionals need to consider a number of differential diagnoses. 

Treatment of paediatric epilepsy, tailored to their seizure type6, currently focuses on managing clinical seizures. However, advances in molecular biology may lead to individualised treatments.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Which anti-epileptic drugs are used to treat paediatric patients with epilepsy?

 

Professors Lagae and Jiang discuss how to optimise treatment of paediatric epilepsy, which currently focuses on managing clinical seizures.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Epilepsy in adults

About 46 million people worldwide have active epilepsy3, which can have a devastating impact on an adult’s quality of life, health and occupational prospects and ability to participate in other activities of daily living13.

Is epilepsy a major public health burden?

In this introductory video, Professor Patrick Kwan discusses the epidemiology of epilepsy and reviews the International League Against Epilepsy (ILAE) 2017 classification of seizure types (Figure 3)14.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Treatment options

What pharmacological and non-pharmacological therapies are available for epilepsy?

Prescribers can choose from a large number of anti-epileptic drugs (AEDs; Figure 4). In this presentation, Professor Kwan discusses the appropriate use of AEDs, which differ in their spectrum of activity.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Explore videos from the Novartis-sponsored satellite symposium ‘Managing Epilepsy in a COVID world’ from EAN 2021 and hear thought-provoking updates on managing epilepsy during the coronavirus disease 2019 (COVID-19) pandemic:

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

  1. Beghi E, Giussani G, Sander JW. The natural history and prognosis of epilepsy. Epileptic Disord. 2015;17(3):243–253.
  2. Helbig I, Abou Tayoun AN. Understanding genotypes and phenotypes in epileptic encephalopathies. Molecular Syndromology. 2016;7(4):172–181.
  3. Beghi E, Giussani G, Abd-Allah F, Abdela J, Abdelalim A, Abraha HN, et al. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):357–375.
  4. Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554.
  5. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures. Epileptic Disord. 2015;17(2):117–123.
  6. National Institute for Health and Care Excellence (NICE) Epilepsies: diagnosis and management. Clinical guidleine [CG37]. Available at: https://www.nice.org.uk/guidance/cg137. Accessed 27 February 2020.
  7. D’Cruz O. Outcome-centered antiepileptic therapy: Rate, rhythm and relief. Implementing AAN Epilepsy Quality Measures in clinical practice. Epilepsy and Behavior. 2015;53:108–111.
  8. Sazgar M, Bourgeois BFD. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol. 2005;33(4):227–34.
  9. Lagae L. Cognitive side effects of anti-epileptic drugs. The relevance in childhood epilepsy. Seizure. 2006;15(4):235–241.
  10. Lagae L. What’s new in: ‘Genetics in childhood epilepsy’. European Journal of Pediatrics. 2008;167(7):715–722.
  11. Raspall-Chaure M, Neville BG, Scott RC. The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol. 2008;7(1):57–69.
  12. Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure. 2008;17(5):405–421.
  13. Perucca E, Covanis A, Dua T. Commentary: Epilepsy is a global problem. Epilepsia. 2014;55(9):1326–1328.
  14. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr Int J Paediatr. 2020;109(6):1088–1095.
  15. Chen B, Kessi M, Chen S, Xiong J, Wu L, Deng X, et al. The Recommendations for the Management of Chinese Children With Epilepsy During the COVID-19 Outbreak. Front Pediatr. 2020;8:495.
  16. French JA, Brodie MJ, Caraballo R, Devinsky O, Ding D, Jehi L, et al. Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology. 2020;94(23):1032–1037.
  17. Baranowski CJ. The quality of life of older adults with epilepsy: A systematic review. Seizure. 2018;60:190–197.
  18. Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58(4):531–542.
  19. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522–530.
  20. Sveinbjornsdottir S, Duncan JS. Parietal and occipital lobe epilepsy: A review. Epilepsia. 1993;34(3):493–521.
  21. Kellinghaus C, Lüders HO. Frontal lobe epilepsy. Epileptic Disord. 2004;6(4):223–39.
  22. Firkin AL, Marco DJT, Saya S, Newton MR, O’Brien TJ, Berkovic SF, et al. Mind the gap: Multiple events and lengthy delays before presentation with a ‘first seizure’. Epilepsia. 2015;56(10):1534–41.
  23. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–1120.
  24. Wang Q, Sun S, Xie M, Zhao K, Li X, Zhao Z. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: A meta-analysis. Epilepsy Res. 2017;135:19–28.
  25. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology. 2010;75(22):1954–1960.
  26. Golyala A, Kwan P. Drug development for refractory epilepsy: The past 25 years and beyond. Seizure. 2017;44:147–156.
  27. Campos MS de A, Ayres LR, Morelo MRS, Marques FA, Pereira LRL. Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta-analyses. Pharmacother J Hum Pharmacol Drug Ther. 2016;36(12):1255–1271.
  28. Beydoun A, DuPont S, Zhou D, Matta M, Nagire V, Lagae L. Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure. 2020;83:251–263.
  29. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (Clinical guidance 137). NICE. https://www.nice.org.uk/guidance/cg137. Accessed 12 January 2021.
  30. Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: A network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;2017(6). doi:10.1002/14651858.CD011412.pub2.
  31. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563.
  32. China Association Against Epilepsy (CAAE). Guidelines on the diagnosis and treatment of epilepsy. 2015. http://www.caae.org.cn/Public/Uploads/20151117/video/564ae8b8c860f.pdf.
  33. Brodie MJ, Kwan P. Newer drugs for focal epilepsy in adults. BMJ. 2012;344(7842). doi:10.1136/bmj.e345.
  34. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–1015.
  35. Sachdeo RC, Gates JR, Bazil CW, Barkley GL, Tatum W, D’Souza J, et al. Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy. Epilepsy Behav. 2006;9(3):457–463.
  36. Dodson WE. Carbamazepine Efficacy and Utilization in Children. Epilepsia. 1987;28(s3):S17–S24.
  37. Djordjevic N, Jankovic SM, Milovanovic JR. Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children. Eur J Drug Metab Pharmacokinet. 2017;42(5):729–744.
  38. Kaur U, Chauhan I, Gambhir IS, Chakrabarti SS. Antiepileptic drug therapy in the elderly: a clinical pharmacological review. Acta Neurol Belg. 2019;119(2):163–173.
  39. Yerby MS. Clinical Care of Pregnant Women with Epilepsy: Neural Tube Defects and Folic Acid Supplementation. Epilepsia. 2003;44(SUPPL. 3):33–40.
  40. Kaushik G, Thomas MA, Aho KA. Psychoactive pharmaceuticals as environmental contaminants may disrupt highly inter-connected nodes in an Autism-associated protein-protein interaction network. BMC Bioinformatics. 2015;16(7):S3.
  41. Pynnonen S, Kanto J, Sillanpää M, Erkkola R. Carbamazepine: Placental Transport, Tissue Concentrations in Foetus and Newborn, and Level in Milk. Acta Pharmacol Toxicol (Copenh). 1977;41(3):244–253.
  42. Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol. 2016;12(2):106–116.
  43. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563.
  44. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75(6):579–82.
  45. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia. 2013;54(1):11–27.
  46. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319.
  47. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
  48. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Review of Neurotherapeutics. 2010;10(6):943–959.
  49. Vajda FJE, Graham J, Roten A, Lander CM, O’Brien TJ, Eadie M. Teratogenicity of the newer antiepileptic drugs - The Australian experience. J Clin Neurosci. 2012;19(1):57–59.
  50. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Breastfeeding in children of women taking antiepileptic drugs: Cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168(8):729–736.
  51. Uddin M, Wang Y, Woodbury-Smith M. Artificial intelligence for precision medicine in neurodevelopmental disorders. npj Digit Med. 2019;2(1):1–10.
  52. Symonds JD, McTague A. Epilepsy and developmental disorders: Next generation sequencing in the clinic. Eur J Paediatr Neurol. 2020;24:15–23.
  53. Sanders SJ, Campbell AJ, Cottrell JR, Moller RS, Wagner FF, Auldridge AL, et al. Progress in Understanding and Treating SCN2A-Mediated Disorders. Trends Neurosci. 2018;41(7):442–456.
  54. Kearney H, Byrne S, Cavalleri GL, Delanty N. Tackling Epilepsy with High-definition Precision Medicine: A Review. JAMA Neurol. 2019;76(9):1109–1116.
  55. Gene therapy for Dravet syndrome – 2020 update – DRACAENA report. http://www.draccon.com/dracaena-report/2020/9/13/gene-therapy-for-dravet-syndrome-2020-update. Accessed 22 June 2021.
  56. Wissel BD, Greiner HM, Glauser TA, Holland-Bouley KD, Mangano FT, Santel D, et al. Prospective validation of a machine learning model that uses provider notes to identify candidates for resective epilepsy surgery. Epilepsia. 2020;61(1):39–48.
  57. Proix T, Truccolo W, Leguia MG, Tcheng TK, King-Stephens D, Rao VR, et al. Forecasting seizure risk in adults with focal epilepsy: a development and validation study. Lancet Neurol. 2021;20(2):127–135.
  58. Engel J. The current place of epilepsy surgery. Curr Opin Neurol. 2018;31(2):192–197.
  59. Jayakar P, Gotman J, Harvey AS, Palmini A, Tassi L, Schomer D, et al. Diagnostic utility of invasive EEG for epilepsy surgery: Indications, modalities, and techniques. Epilepsia. 2016;57(11):1735–1747.
  60. Youngerman BE, Oh JY, Anbarasan D, Billakota S, Casadei CH, Corrigan EK, et al. Laser ablation is effective for temporal lobe epilepsy with and without mesial temporal sclerosis if hippocampal seizure onsets are localized by stereoelectroencephalography. Epilepsia. 2018;59(3):595–606.
  61. Barbaro NM, Quigg M, Ward MM, Chang EF, Broshek DK, Langfitt JT, et al. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: The randomized, controlled ROSE trial. Epilepsia. 2018;59(6):1198–1207.
  62. Englot DJ, Rolston JD, Wright CW, Hassnain KH, Chang EF. Rates and Predictors of Seizure Freedom with Vagus Nerve Stimulation for Intractable Epilepsy. Neurosurgery. 2016;79(3):345–353.
  63. Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S, Gursky J, et al. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open. 2020;5(2):314–324.
  64. Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, et al. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia. 2020;61(6):e49–e53.
  65. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690.
  66. Balloy G, Leclair-Visonneau L, Péréon Y, Magot A, Peyre A, Mahé PJ, et al. Non-lesional status epilepticus in a patient with coronavirus disease 2019. Clin Neurophysiol. 2020;131(8):2059–2061.
  67. Somani S, Pati S, Gaston T, Chitlangia A, Agnihotri S. De Novo Status Epilepticus in patients with COVID-19. Ann Clin Transl Neurol. 2020;7(7):1240–1244.
  68. Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, et al. Focal status epilepticus as unique clinical feature of COVID-19: A case report. Seizure. 2020;78:109–112.
  69. Mostacci B, Licchetta L, Cacciavillani C, Di Vito L, Ferri L, Menghi V, et al. The Impact of the COVID-19 Pandemic on People With Epilepsy. An Italian Survey and a Global Perspective. Front Neurol. 2020;11. doi:10.3389/fneur.2020.613719.
  70. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
  71. Kuroda N. Epilepsy and COVID-19: Updated evidence and narrative review. Epilepsy Behav. 2021;116. doi:10.1016/j.yebeh.2021.107785.
  72. Assenza G, Lanzone J, Brigo F, Coppola A, Di Gennaro G, Di Lazzaro V, et al. Epilepsy Care in the Time of COVID-19 Pandemic in Italy: Risk Factors for Seizure Worsening. Front Neurol. 2020;11. doi:10.3389/fneur.2020.00737.
  73. Miller WR, Von Gaudecker J, Tanner A, Buelow JM. Epilepsy self-management during a pandemic: Experiences of people with epilepsy. Epilepsy Behav. 2020;111. doi:10.1016/j.yebeh.2020.107238.
  74. Asadi-Pooya AA, Attar A, Moghadami M, Karimzadeh I. Management of COVID-19 in people with epilepsy: drug considerations. Neurol Sci. 2020;41(8):2005–2011.
  75. Association of British Neurologists. Association of British Neurologists Guidance on Vaccination for COVID-19 and Neurological Conditions. www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/ABN_Guidance_on_COVID-19_Vaccinations_for_people_with_neurological_conditions_9.1.21.pdf. Accessed 22 June 2021.
Welcome:

The One Neuroscience and Pain Learning Zone has been developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with content provided by Novartis Pharma AG. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. CNS Learning Zone: FUSE ID: 8503, 104429, 127972, 136154 and Pain Learning Zone: FUSE ID:11501.